Search

Adam Blumenthal

Adam Blumenthal has over 10 years’ experience in Investment Banking and Corporate Finance with deep exposure to Australian and International markets, having provided capital raising and financing solutions to an extensive number of unlisted and listed companies. Mr Blumenthal has played a lead role in advising and supporting multiple organisations across a broad spectrum of industries, using his experience and extensive network of international contacts to provide corporate advisory and capital markets input. Mr Blumenthal has successfully worked on several medical marijuana deals spanning Israel, Canada and Switzerland. He has also been actively involved in Mining, Cyber Security, Health Care and IT sectors. Outside of his formal business activities, Mr Blumenthal has lectured at a leading Sydney University covering corporate governance, corporate social responsibility and ASX listings – at an undergraduate and postgraduate level. Mr Blumenthal holds a Bachelor of Commerce (B.COM), Master of International Relations (MIR) and Master of Business Administration (MBA) degrees.
Bio last updated 08 Dec 2018

Access to our data for Adam Blumenthal is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Adam Blumenthal is linked to 3 organisations which are included in 1 list - Public Companies - Industrial.

To see the data you will need to .

Total Shareholder Return as at 30/11/18

1 year TSR5 year TSR
163rdQueste Communications21%-5%
748thCreso Pharma-64%0%
801stRace Oncology-75%0%
741 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Roles

2016
Co-Founder, Non-Executive Director
2016
Non-Executive Director
Year started and most recent title

Revenue

189th↑Creso Pharma$244k
190th↓Wavenet International$239k
191st↓NetLinkz$226k
193rd↓Queste Communications$172k
194th-Race Oncology$170k
238 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer